James (jay)
Bio-Pharmaceuticals
Diagnosezentrum Donaustadt
Ireland
Biography
Prior to joining Novartis Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus of the Bradner laboratory has been the study of BET bromodomain proteins and their function in gene control, innovating chemical probes and investigational drugs to study and treat cancer. Further, the Bradner laboratory pioneered a first all-chemical strategy for targeted protein degradation. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 200 scientific publications and 30 United States patent applications.
Research Interest
Bio-Pharmaceuticals
